STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Read More…
Industry, Sector and Symbol
Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
SectorMedical
Phone626-303-7902
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$123.95 million
Profitability
Miscellaneous
Employees475
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable
STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions
What is STAAR Surgical's stock symbol?
STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."
How were STAAR Surgical's earnings last quarter?
STAAR Surgical (NASDAQ:STAA) posted its quarterly earnings results on Wednesday, July, 31st. The medical instruments supplier reported $0.14 EPS for the quarter, topping the Zacks' consensus estimate of $0.10 by $0.04. The medical instruments supplier earned $39.66 million during the quarter, compared to analyst estimates of $40.10 million. STAAR Surgical had a return on equity of 12.81% and a net margin of 5.80%. View STAAR Surgical's Earnings History.
When is STAAR Surgical's next earnings date?
How can I listen to STAAR Surgical's earnings call?
STAAR Surgical will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for STAA?
1 Wall Street analysts have issued 12-month price targets for STAAR Surgical's shares. Their forecasts range from $38.00 to $38.00. On average, they expect STAAR Surgical's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 42.5% from the stock's current price. View Analyst Price Targets for STAAR Surgical.
What is the consensus analysts' recommendation for STAAR Surgical?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical.
Has STAAR Surgical been receiving favorable news coverage?
Media coverage about STAA stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. STAAR Surgical earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for STAAR Surgical.
Who are some of STAAR Surgical's key competitors?
Some companies that are related to STAAR Surgical include Moderna (MRNA), China Biologic Products (CBPO), Envista (NVST), argenx (ARGX), Healthscope (HSO), Amedisys (AMED), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Repligen (RGEN), Premier (PINC), BTG (BTGGF), Aurora Cannabis (ACB), Healthequity (HQY), Spark Therapeutics (ONCE) and Ablynx (ABLYF).
What other stocks do shareholders of STAAR Surgical own?
Who are STAAR Surgical's key executives?
STAAR Surgical's management team includes the folowing people:
- Ms. Caren L. Mason, CEO, Pres & Director (Age 65)
- Ms. Deborah J. Andrews, Chief Financial Officer (Age 62)
- Dr. Keith Holliday, Chief Technology Officer (Age 56)
- Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 57)
- Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations, Direct Markets- Europe & China (Age 54)
Who are STAAR Surgical's major shareholders?
STAAR Surgical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dfpg Investments Inc. (0.03%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Institutional Ownership Trends for STAAR Surgical.
Which institutional investors are buying STAAR Surgical stock?
How do I buy shares of STAAR Surgical?
Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is STAAR Surgical's stock price today?
One share of STAA stock can currently be purchased for approximately $26.66.
How big of a company is STAAR Surgical?
STAAR Surgical has a market capitalization of $1.19 billion and generates $123.95 million in revenue each year. The medical instruments supplier earns $4.97 million in net income (profit) each year or $0.28 on an earnings per share basis. STAAR Surgical employs 475 workers across the globe.View Additional Information About STAAR Surgical.
What is STAAR Surgical's official website?
How can I contact STAAR Surgical?
STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]
MarketBeat Community Rating for STAAR Surgical (NASDAQ STAA)
MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe STAA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STAA will underperform the S&P 500 over the long term. You may vote once every thirty days.
